PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

VOL.
17
1982

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume contents, Author index
and Subject index to
Volume 17

PERGAMON PRESS OXFORD NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1983, U.S. $800.00 including postage and insurance. 2 years, 1983/84, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually.
Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 17, 1982, Numbers 1–3

CONTENTS

Number 1

PAGE

Age-dependent changes in the responsiveness of the reproductive system to pharmacological agents: *R. W. Steger* 1
The developing mammalian olfactory system and its role in mediating the effects of psychotropic and physiologically active odorous agents: *D. M. Stoddart* 65
Developmental aspects of renal pharmacology: *B. Noordewier and J. B. Hook* 85
Pharmacokinetics – compartmental representation: *G. Segre* 111
Actions of nicotine and smoking on circulation: *C. Su* 129

Number 2

Dosage regimen design: *C. L. DeVane and W. J. Jusko* 143
Mediators of cellular immune reactions: *J. M. Hanson, V. M. Rumjanek and J. Morley* 165
Drug interactions at (pharmacodynamically active) receptor sites: *J. S. Schou* 199
Drug interactions involving the displacement of drug from plasma protein and tissue binding sites: *P. F. D'Arcy and J. C. McElnay* 211
Choice of drug treatment in asthma: *T. J. H. Clark* 221
Steroids and asthma: *A. D. Milner* 229
Histamine antagonists and asthma: *N. M. Eiser* 239
Diet-induced thermogenesis: *N. J. Rothwell, M. J. Stock and D. Stribling* 251
Drug delivery to the eye: *G. C. Y. Chiou and K. Watanabe* 269

Number 3

Antiallergic compounds: *R. J. Davies and I. Moodley* 279
Bronchodilator drugs: *A. E. Tattersfield* 299
Drugs with a class III Antiarrhythmic action: *R. S. Bexton and A. J. Camm* 315
Thermoafferent systems and their adaptive modifications: *K. Brück and P. Hinckel* 357
Time-dependent pharmacokinetics: *R. H. Levy* 383
Inhibitors of adenosine deaminase: *R. P. Agarwal* 399
Effects of nicotine on conditioned and unconditioned behaviors in experimental animals: *J. S. Hendry and J. A. Rosecrans* 431

OL.
17
982

AUTHOR INDEX

Agarwal, R. H. 399

Bexton, R. S. 315
Brück, K. 357

Camm, A. J. 315
Chiou, G. C. Y. 269
Clark, T. J. H. 221

D'Arcy, P. F. 211
Davies, R. J. 279
DeVane, C. L. 143

Eisner, N. M. 239

Hanson, J. M. 165
Hendry, J. S. 431
Hinckel, P. 357
Hook, J. B. 85

Jusko, W. J. 143

Levy, R. H. 383

McElnay, J. C. 211
Milner, A. D. 229
Moodley, I. 279
Morley, J. 165

Noordewier, B. 85

Rosecrans, J. A. 431
Rothwell, N. J. 251
Rumjanek, V. M. 165

Schou, J. S. 199
Segre, G. 111
Steger, R. W. 1
Stock, M. J. 251
Stoddart, D. M. 65
Stribling, D. 251
Su, C. 129

Tattersfield, A. E. 299

Watanabe, K. 269

SUBJECT INDEX

N-Acetylprocainamide, serum levels and dose 157
Adenine structure 401
Adenosine deaminase
  association and dissociation rate constants 408–12
  erythrocyte, inhibitor effects 405
  inhibitor interaction 403–12
  sources 409
Adenosine deaminase inhibitors 399–424
  Ackermann–Potter plot 404, 406
  adverse reactions 422
  AMP deaminase effects 418, 419
  antiviral activity and Ara-A 417
  chemotherapeutic effects 415–17
  cytotoxicity 415–17
  elimination and excretion 420, 421
  immunosuppression 417, 418
  kinetic analysis 404–7
  K_i values 406
  metabolic effects 412–15
  metabolism 421, 422
  nucleic acid effects 413–15
  platelet aggregation 419
  protein synthesis 413–15
  reaction mechanism 402
  structure 401
  structure–activity relationships 399–401
  9-substituted adenines 400
  synthesis 399–403
  tight binding 408
  tissue course 404
  tissue distribution 420
  transition state affinity 402, 403
Adenyl cyclase, drugs affecting 209
Adrenaline structure 301
α-Adrenergic antagonists, bronchodilation 308
β-Adrenergic antagonists in asthma 292
  administration 304, 305
  choice and route 305
  duration of action 306
  formulae 301
  inhalation and nebulization 306, 307
  metabolism 300–7
Adverse reaction
  adenosine deaminase inhibitors 423, 424
  amiodarone 328–35
  bretylium 339
  corticosteroids 231–3
  sotalol 344
  sympathetic amines and receptors 300
Afferent systems and temperature 357–70
  central nervous 360–72
Affinity binding studies 200, 201
Age
  drug effects on reproductive system 1–46
  follicular development 20
  glomerular filtration rate 92
  gonadotropin releasing factor response 27–9
  gonadotropin secretion control 39–41
  ovarian secretion 18, 19
  reproductive decline and opioid peptides 34, 35
  steroid negative feedback 11, 12, 14
  testicular steroids 21, 22
  and uterine weight in rats 7
β-Agonist aerosols, U.K. sales 299
Airways, autonomic control of calibre 299, 300
Aldosterone and renal development 95–7
Allergen provocation 280
Amiodarone 315
  adverse reactions 328–35
  angina pectoris 322, 323
  antiarrhythmic effects 323–8
  atrial potentials 317
  atrial and ventricular potential 316
  cardiac action potential 318
  cardiac rhythm 329
  clinical electrophysiology 319–21
  dosage 328
  drug interactions 333, 334
  hemodynamic effects 328, 329
  intravenous 319
  myocardial effects 316–19
  myxedema 317
  ophthalmic effects 330, 331
  oral 321
  pharmacokinetics 321, 322
  skin effects 331
  structure 315
  sudden death 327
  thyroid effects 331–3
  ventricular arrhythmias 326, 327
AMP, cyclic
  drug interactions 208
  and histamine secretion 282
Angina pectoris, amiodarone effects 322, 323
Anion transport 97, 98
Antiallergic drugs 279–92
  new 288–91
  sodium cromoglycate 280–7
Antiarrhythmic drugs, Class III 315–48
Antihistamines *see* histamine antagonists
Antimuscarinic drugs, action 307
Arachidonic acid metabolism 190
Aspirin in asthma 286
Asthma
  acute severe 230, 233, 234
  chronic 234–6
  corticosteroids 225
  drug choice 221–7
  frequency and persistence 222, 223
  histamine antagonists 239–47
  induced 285, 286
  inhaled therapy 225
  mast cell mediators 280, 281
  nocturnal 226
  prophylaxis 226
  route of drugs 225
  severity and drugs 222
  steroid role 229–36 *see also* corticosteroids
  treatment guidelines 223, 224
  treatment used and effectiveness 221
Asthmatic reaction 279

Atrial fibrillation and flutter 324

Basal body temperature and hormones 5
Beclomethasone dipropionate
  dose 235
  and growth velocity 234
Behavior and nicotine 431–52
  avoidance 441–8
  schedule-controlled 436–41
  shuttle response 441
  stimulus control 448–51
  unconditioned 431–6
Bradycardia–tachycardia syndrome 324
Bretylium
  adrenergic effects 335
  adverse reactions 339
  antiarrhythmic effects 337–9
  cardiac electrophysiological effects 336, 337
  hemodynamic effects 336, 337
  pharmacokinetic effects 337–9
Bronchial provocation effects 229, 230
Bronchodilator drugs 291, 292, 299–309
  clinical studies 308
Brown adipose tissue
  noradrenaline effects 260
  thermogenesis 252
  thyroid hormone effects 258, 259

Calcium antagonists and bronchodilation 309
Carbon monoxide
  atherosclerosis 130, 131
  circulatory effects 129, 130
Cardiac arrest 327
Catechol-*O*-methyl transferase, action 301
Cellular immune reactions 166–92
  mediators *see* lymphokines
Central nervous afferent system
  pontine units 361
  subcoeruleus system 360, 361
Chlorpheniramine
  histamine response 244
  respiratory effects in asthma 242, 243
Chronopharmacokinetics 383
  absorption, time dependency 384–6
  csf drug concentration 389
  enzyme activity 388
  induction, auto- and hetero- 390–4
  plasma binding 388, 389
  renal clearance 389
  systemic clearance 386
Cimetidine
  histamine response 244
  respiratory effects in asthma 242, 243
  structure 207
Clearance 119, 120
  determinations 156–9
  maintenance dose calculation 159
Clemastine, induced asthma 285
Clofilium, Class III antiarrhythmic effects 346, 347
Clonazepam
  chronopharmacokinetics 387
  induction time-course 392, 393
  plasma concentrations 393
Coformycin
  association rate constants 409
  K_i estimation 407–9
  structure 401

Compartment
  clearance 119, 120
  definition 113, 114
  drug distribution 212
  oscillation in systems 121, 122
  residence time 122–5
  transfer constants 116–18
  transfer times 122–5
  volume 114–16
Corpus luteum, prostaglandin effects 43
Corticosteroid, release control 67
Corticosteroids in asthma 229–36, 291, 292
  acute severe asthma 230, 233
  availability 229
  chronic asthma 231
  chronic effects 232
  dosage of topical 235
  efficacy 229
  evaluation 229–30
  growth suppression 232
  indications 233–6
  topical 231
  topical toxicity 232, 233
  toxicity 231–3

2-Deoxycoformycin 401
  association rate constants 409
  K_i estimation 407–9
Diet and thermogenesis 251–64
Digoxin–amiodarone interaction 334
Diphenhydramine structure 207
Displacement interactions 218 *see also* plasma protein
  mechanisms 218
Diuretics
  effects on kidney 102–6
  thiazide 105
Dopamine, gonadotropin inhibition 36
Dosage 143–61
  and active metabolites 160
  clearance rate 156–9
  complications 159–61
  computer aids 159
  disease states 160
  factors to consider 152
  interval 148, 149
  intravenous infusion 149–51
  linear drug deposition 145–51
  multiple bolus 147, 148
  nonlinear drugs 151–3
  optimization methods 153
  serum concentration 144, 145
  serum concentration feedback 154–6
  single 145–7
  time-dependency 383
Drugs *see also* individual drugs and classes
  antiallergy 279–92
  antiarrhythmic 315–48
  compartment distribution 212
  linear 145–51
  neural control of gonadotropin release 35–41
  nonlinear 151–3
  renal effects 102–6
  and reproductive system 1–46
  sex–age effects 1–46
  tissue binding 217, 218
Drug interactions
  β-adrenoceptors 204
  adverse 202
  affinity binding studies 200, 201

amiodarone 333, 334
antihistamines 207
antirheumatic and connective tissue 206
cardiovascular 205, 206
cholinergic receptors 204, 205
drug–drug mechanism 199
mechanisms 215, 216
pharmacodynamic targets 201
plasma protein displacement 211–18
receptor sites 199–208
respiratory system 207, 208
sympathetic transmission site 202, 203

Elimination
drug deposition 145
kidney 215
liver 215
plasma protein binding of drugs 215
Enzyme activity, time dependency 388
Erythro-9-(2-hydroxyl-3-nonyl)adenine
association rate constants 409
K_i estimation 407, 409
structure 401
Estradiol benzoate and prolactin in rats 17
Estrogens, cyclic patterns 5
Estrus induction 77
Ethinyl estradiol and rat uterus weight 7
Exercise-induced bronchostriction 230
and sodium cromoclycate 286
Exocytosis and nicotine 135
Eye
amiodarone effects 330, 331
arterial nourishment 274
blood barriers 274, 275
circulation 273, 274
drops and solutions 270, 271
drug delivery 269–76
injections 273–6
insert polymers 272, 273
intraocular injections 275
nature 269
ointments 271
oral drugs 276
penetrability 270
perfusion 271, 272
soft contact lenses and drugs 272
sprays 271
subconjunctival injections 275
topical drugs 269, 270

Feedback
serum concentration 154–6
and steroid control 8–10
Fluocinolone-16, 17-acetonide, dose in asthma 235
Follicle stimulating hormone (FSH)
cyclic pattern 5
and estradiol benzoate 16, 17
exposure to males 74
progesterone effects 17
response in puberty 26
Furosemide and sodium excretion in neonatal rats 103, 104

Gentamicin clearance 156
Glomerular filtration rate
developing animals 90–3
increase and age 92
Glucagon and thermogenesis 260, 261
Glucose–insulin system, compartmental scheme 122
Gonadotropin
control system, female 4
control system, male 2, 3
drugs affecting secretion control 35–7
regulation and prostaglandins 45, 46
secretion control and age 39, 40
Gonadotropin releasing hormones
agonists 31
extrahypothalamic effects 30, 31
metabolism 30
pituitary response modulation 23, 24
reproductive function 23
response and puberty 25–7
senescence 27–9
steroid response modulation 24, 25
Granolocytes
effects and changes 174
lymphokine activation 173–5

Histamine
dose–response in asthma 244
endogenous rhythm 239
secretion mechanism 281–3
structure 207
Histamine antagonists
antigen response 245
asthma 239–47
bronchial tone 241–3
clinical trials 241
histamine response 243
physiological effects 240, 241
5-Hydroxytryptamine (serotonin)
thermoregulation 365–70
Hypothalamus
cold responsive unit 366
recording and stimulation sties 366
temperature response 363

Imipramine, serum concentration and doses 155
Immunoglobulin E in asthma 281
Imprinting, precocial mammals 70, 71
Inflammation, lymphokine role 187, 188
Inflammatory reactive factor
bioassay 177
purification 183
Inhibin 9, 10
Insulin and thermogenesis 260
Interferon
bioassay 177
properties 178, 182
purification 183
Interleukin 1, lymphokine secretion 189, 190
Interleukin 2
lymphatic secretion 190
properties 178
Ipratropium 307
Isocoformycin structure 401

Ketotifen
in asthma 245, 246, 289–91
induced asthma 285
Kidney
effects of drugs 97–102

Ligandin, neonatal kidneys 100, 101

Lodoxamide in asthma 289
Luteinizing hormone (LH)
exposure to males 74
and LH–RH response in rats 28
morphine effects 34
response and puberty 28
serum levels and estradiol benzoate 15, 16
serum levels and progesterone 16
Luteinizing hormone-releasing hormone (LH–RH)
and LH in rats and age 29
Luteinizing releasing factor, response and puberty 27
Lymph node permeability factor 166, 167
Lymphocyte, consequences of activation 169–71
Lymphocyte mitogenic factor
assay 175
properties 178
purification 179
Lymphokines
bioassays 176, 177
biochemical properties 177–86
biological effects 167
delayed hypersensitivity 184
fatty acids and activity 185
generation 167, 168
granulocyte effects 173
lymphocyte effects 169–71
macrophage effects 171–3
osteoclast effects 174
physiological role 186, 187
protein 185
purification 179
role in inflammation 187, 188
stability 177
vascular endothelium 174–6
Lymphokine secretion regulation 188–92
aspirin 191
indomethacin 191
interleukin 1, 189, 190
levamisole 192
prostaglandins 189–91
steroids 192
Lymphotoxin 176, 177
lymphoid cells 180
properties 178, 180

Macrophage, lymphokine activation 171–3
Macrophage activating factor 182
Macrophage chemotactic factor
assay 176
properties 181
Macrophage migration inhibition factor 166–8
assay 176
properties 178, 180, 181
Mast cell, mediators in asthma 280, 281
Menstrual cycles, induction by gonadotropin releasing hormone replacement 28
Meobentine
action potential 346
antiarrhythmic effects 346
pharmacokinetics 346
pharmacology 345
structural formula 345
Metabolic cascade and clearance 158
Models
compartmental systems 111
induction time-course 391–4
thermoafferent connectivity 374

Monoamine oxidase inhibitors
noradrenaline storage 202, 203
tyramine effects 202

Nicotine
adrenergic neurone action 139
adrenergic transmitter release 132–8
amount consumed, U.S.A. 431
analog structures 450
animal and human effects 451, 452
atherosclerosis 130, 131
avoidance behavior 441–8
behavioral effects 431–52
circulatory effects 129, 130
dose discrimination by rats 449
established avoidance 444
exocytotic release 135–8
exploratory behavior 434
lever pressing for water 436–8, 440
maze learning 433
mechanism of action 133, 134
monkeys, lever pressing 439
neuronal uptake 134
norepinephrine, metabolic fate 137, 138
pole jumping and shock in rats 444
presession and avoidance 441–3
presynaptic modulation 137
regional effects 131, 132
schedule controlled responding 436–41
spontaneous motor activity 432, 433
spontaneous rearing 434
and stimulus control of behavior 448–51
structure 450
sympathomimetic effects and tetrodotoxin 135, 136
tolerance 446–8
transmitter release facilitation 138, 139
unconditioned behavior 431–6
wheel running 435

Odors
maternal and artificial young 69, 70
and psychosexual development 75
urinary 74
Olfactory biology, future of 79
Olfactory system
adult 75–8
adult human 77, 78
developing infants 71–3
developing mammals and drugs 65–80
embryology 68
estrus induction 77
evolutionary origin 75, 76
functions and role 65
neonatal development 68–71
neural connections 67
position in vertebrate brain 66
pregnancy 77
sex 66
sexual development 73
Opioid peptides
age-related reproductive decline 34, 35
gonadotropin effects 32, 33
prepuberty gonadotropin 33, 34
prolactin effects 32, 33
Organic anion transport, kidney effects 97, 98
Osteoclasts, lymphokine effects 174

Osteoclast activating factor 177
properties 178
purification 184
Ovary
gonadotropin effects 17–20
secretion and age 18
steroid maturation 17, 18
Ovulation
gonadotropin effects 19
prostaglandin role 42
Oxatomide in asthma 289, 290

Para-aminohippurate transport, penicillin effects and excretion 98, 99, 102
Penicillin and renal function in rats 97–9
Pharmacokinetics
compartmental systems 111–25
mathematical models 111–13
nonlinear drugs 152
physiological 120, 121
time dependent 383–95 *see also* chronopharmacokinetics
Pharmacologic effects 143, 144
Phenylephrine, oxygen consumption and diet 256
Phenytoin, steady state serum and dose 153
Pheromones
maternal 71, 72
rat excreta 72
Pimozide 39
Plasma protein
competitive displacement 213
displacement, factors affecting 217
displacement and volume of distribution of drug 213, 214
drug binding and kinetics 211
properties 211
Precocial mammals 70
Prednisolone, growth suppression 232
Pregnancy, odor effects 77
Procainamide
clearance and dosage 157
serum concentration and dose 157
Prolactin
age and secretion control 41
hypothalamus inhibition and control 37, 38
inhibiting and releasing factors 32
release induction 39
secretion regulation 14
Promethazone structure 207
Prostaglandins
corpus luteum control 43
female reproduction 42
gonadotropin regulation 45, 46
lymphokine secretion 189–91
male reproduction 42
ovarian steroidogenesis 43
ovulation 42
renal function 97
tubule contractility 44
uterus contractility 44, 45
Prostaglandin E_2 and bronchodilation 309
Puberty
gonadotropin and prolactin secretion control 38, 39
response to gonadotropin 26
Pulmonary mast cells, histamine effects 241

Raphé system
thermogenesis inhibition 369, 370
thermoregulation 365–9

Receptors
β-adreno and thermogenesis 254–6
cholinergic, location 200
drug interactions 199–218
H_1, H_2 and antagonists 207, 240
pharmacodynamic 199
thermal 359
Renal blood flow and function 88–90
indomethacin 106
maturation 89
microspheres in dogs 90
neonate puppies 89
species and development 88
Renal clearance, time-dependency 389
Renal development 85–8
ontogenetic heterogeneity 85
postnatal 87
reabsorption 93–5
renin–angiotensin 95–7
tubular 86
Renal function
diuretics 102–6
respiratory distress function 105
Renal lipid metabolism, substrate stimulation 100
Renal microsomal enzymes, substrate stimulation 101
Renal pharmacology, developmental aspects 85–106
Renal protein synthesis, substrate stimulation 100
Renin–angiotensin–aldosterone in developing mammals 95–7
Reproductive system and drugs 1–46
female 3–5
gonadotropins 17–23
hypothalamic releasing factors 33–5
male 1–3
opioid peptide effects 32–5
prostaglandins 41–6
steroids 5–17
Respiratory flow rate and salbutamol 230

Salbutamol
respiratory effects 230, 237
structure 301
Sexual development, urine odors 74
Shivering 363
Slow reacting substance of anaphylaxis, nature 185
Smell *see* olfactory, odors
Smoking *see also* carbon monoxide, nicotine
circulatory effects 129–39
Sodium, excretion, reabsorption and development 93–5
Sodium cromoglycate
clinical trials 286, 287
discovery 283
guinea-pig studies 284
human studies 284–7
induced asthma 285, 286
mechanism of action 287
monkey tests 284
rat tests 284
response to allergen 280
Sotalol
adverse reactions 344, 345
antiarrhythmic effects 342, 343
clinical electrophysiology 341
intravenous studies 343
myocardial electrophysiology 341
oral effects 344
pharmacokinetics 341

pharmacology 340
structural formula 340, 341
Spermatogenesis, gonadotropin effects 22, 23
Spinal cord, thermoafferents 372, 373
Steroids *see also* corticosteroids
age effects 5
effects on female 5–7
effects on males 7, 8
feedback, prepubertal response 10, 11
gonadotropins 17–20
negative feedback 8
positive feedback and maturation 12, 13
rat estrus cycle 6
sex accessory organ effects 5
thermogenesis role 261, 262
Sulphur dioxide in asthma 286

Temperature regulation
cybernetic concepts 357, 358
neurophysiological concept 358, 359
Terbutaline structure 301
Testes
gonadotropin effects 20–3
secretion and age 20, 21
secretion maturation 20
Testosterone
age and prostatic weight 7, 8
NIH-LH-137 effects 21
Tetrodotoxin
and exocytosis with nicotine 135
sympathomimetic nicotine effects 136
Theophylline
factors affecting clearance
problems in asthma 225
Thermoafferent systems 357–76
cold adaptive modifications 371
connectivity model 375–7
lower brain stem stimulation 363, 364
neuron adaptive behavior 370–2
noncutaneous sources 372–5
noradrenergic 364
peripheral cutaneous 359
pontine stimulation sites 363
raphé stimulation 367, 368
raphé system 365
serotonin effects 365–70
skin cooling 371
spinal cord 359, 360, 372
subcoeruleus unit response 361
thermosensitive areas 373
trigeminal nucleus 359

Thermogenesis
α-adrenoceptor 256
β-adrenoceptor 254, 255
brown adipose tissue metabolism 257
catecholamine control 254–8
central control 253, 254
diet-induced 251–64
glucagon 260, 261
hormones affecting 262, 263
insulin effects 260
mechanism 251–3
nonshivering 251
noradrenaline 260
steroids 261, 262
subcoeruleus lesions 364
subcoeruleus stimulation 362
thyroid hormone effects 258
Thermosensitive neurons 358, 359
Thiazinamium 242
Thyroid gland function and amiodarone 332, 333
Time dependency *see also* chronopharmacokinetics
chemically-induced 390–4
Tolerance to nicotine 446–8
Tracheobronchial smooth muscle, histamine effects 240, 241
Transfer constants 116–18
detailing 120, 121
Transfer factor, molecular weight 185
Triamcinolone-16, 17-acetonide, dose in asthma 235
Tricyclic antidepressants, drug interactions 203
Type I hypersensitivity mediators 279

Valproic acid, diurnal plasma oscillations 386
Vascular endothelium, lymphokine effects 174–6
Vascular permeability increasing factor 183
Volume of distribution 114–16
plasma protein displacement 213, 214
Vomeronasal organ 67

Warfarin, protein binding and drugs 216
Water excretion, reabsorption and development 93–5

Xanthine derivatives in asthma 292

Wolff–Parkinson–White syndrome
arrhythmias 325, 326

OL.
17
982